Alliance Panels

A prevalent issue with historical genotyping tools is their bias toward a small number of ethnicities, leaving significant portions of humanity underrepresented in classic genotyping workflows. As an example, microarray platforms only offer fixed content updated occasionally, compounding this challenge.



Researchers can solve these inefficiencies and inequities by utilizing target capture-based NGS workflows with probe panels designed for diversity and flexibility.



As part of Twist’s growing Targeted GBS portfolio, the Twist Diversity SNP Panel gives researchers a new flexible ethnicity-neutral gold standard to use for GBS.



Scientists have the freedom to use the panel as a stand-alone genotyping panel or as a spike-in into the Twist Human Comprehensive Exome panel. Its design is also customizable—additional probes covering regions of interest can be synthesized on Twist's DNA synthesis platform.



The Twist Diversity SNP Panel content was curated in partnership with leaders at the Regeneron Genetics Center. Designed to integrate into existing fully automated exome processing workflows, this panel provides base calls and imputed variants.

Genotype imputations can be calculated using open source tools available. Please reach out to Customer Support to get a copy of our imputation guide to getting started with imputation analysis tools.

 

Note: The Diversity SNP panel content has not been fully validated through the complete Twist workflow. For recommendations on assay set-up, please contact Twist Customer Support.

Methylation sequencing is a sensitive tool for detecting and tracing the origin of cancer cells. But like any sequencing project, there is a tradeoff between breadth and depth of coverage. If you’re ready to focus on cancer-specific methylation patterns, this is the panel for you. Experts at AnchorDx partnered with Twist to create a custom target enrichment panel that focuses specifically on targets relevant to 31 different cancers. 

The Twist Alliance Pan-cancer Methylation Panel - 1.5 MB provides deep coverage of clinically focused targets that allow for the study of methylation patterns that may be relevant to early cancer detection and diagnosis from tumor and liquid biopsy samples. Designed in collaboration with experts at AnchorDx and constructed using Twist’s world-class oligonucleotide synthesis platform, this panel provides a high on-target rate and high uniformity, and has been validated with the Twist Methylation workflow using liquid biopsy samples of breast cancer, colorectal cancer, and non-small cell lung cancer.

Interested in seeing which genes are covered? Contact us at customersupport@twistbioscience.com

Panel Design

• 31 cancer types, 47 disease entities, based on TCGA database
• 13,090 Probes 
• 126k CpG sites involved
• ~12k Differentially Methylated Regions (DMRs)
• 9k of 12k (74%) overlapped with the CpG islands

Note: The Twist Alliance Pan-cancer Methylation Panel - 1.5 MB is not ISO-13485 certified

The Twist Alliance Clinical Research Exome helps support the Broad Institute Genomics Platform and was designed using validated data from clinical patient samples. The panel leverages Twist’s flexible NGS platform to customize content easily and quickly, resulting in a comprehensive survey of the exome with supplemental enrichment of clinically relevant areas of the genome related to cancer as well as rare and inherited diseases. By leveraging the best-in-class uniformity of Twist NGS probes, the assay enables a per sample cost and throughput efficiency that Broad has already leveraged to process more than 250,000 samples to date, keeping it on the leading edge of exome sequencing.

The full design of this panel includes the Twist Core exome, the mitochondrial genome, and additional validated coding and non-exonic regions of interest such as the ACMG73 genes, supplemental coverage of regions from OMIM and COSMIC, and specific Broad-defined targets. 

Note: The Twist Alliance Clinical Research Exome - 34.9 MB content has not been fully validated through the complete Twist workflow. For recommendations on assay set-up, please contact Twist Customer Support. 

Note: The Twist Alliance Clinical Research Exome - 34.9 MB is not ISO-13485 certified.

Where routine testing has failed to provide a diagnosis, physicians often turn to DNA sequencing panels for answers, particularly when a heritable disease is suspected. But without expert guidance, it can be hard to know which panel is the right panel.

Drawing on decades of experience in clinical genomics, Victorian Clinical Genetics Services (VCGS) has partnered with Twist to design a diagnostic panel—Twist Alliance VCGS Exome - 40.1 MB—that covers the whole exome, with dedicated coverage boosting over clinically relevant genes (Mendeliome). In designing this panel, special care was given to ensuring additional coverage of clinically relevant loci that fall outside the gene coding regions traditionally targeted by exomes (i.e. known pathogenic loci in non-coding regions).

The Twist Alliance VCGS Exome - 40.1 MB panel is a best-in-class, highly uniform panel that can help streamline the identification of heritable disease-linked alleles, be it through carrier screening or pre- and post-natal testing.

Note: The Twist Alliance VCGS Exome - 40.1 MB content has not been fully validated through the complete Twist workflow. For recommendations on assay set-up, please contact Twist Customer Support.

Note: The Twist Alliance VCGS Exome - 40.1 MB is not ISO-13485 certified.

For Research Use Only. Not for use in diagnostic procedures

Diagnosis of rare diseases presents many challenges for physicians and can lead patients on a long diagnostic odyssey.  DNA sequencing panels can provide physicians answers to these challenges and resolution for patients.  As a leader in rare disease diagnostics, CENTOGENE has partnered with Twist to design a series of target enrichment capture panels, providing comprehensive tools to aid in rare disease and hereditary oncology diagnosis.  

The Twist Alliance CNTG Exome - 41 MB provides highly uniform coverage of the entire exome as well as full coverage of the mitochondrial genome. Combining insights from CENTOGENE’s bio/databank with exceptional omics technology, the Twist Alliance CNTG Exome - 41 MB increases diagnostic yield compared to standard whole exome sequencing and covers a broad spectrum of disorders encompassing >7,000 rare diseases.  

Note: The Twist Alliance CNTG Exome - 41 MB  is not ISO-13485 certified.

Panel Information

• Total Probes 483K

• Twist Human Comprehensive Exome 396.1K

• Twist Mitochondrial Panel 139

• Twist Alliance Centogene Rare Disease Panel 78.8 K

• Centogene Spike-In 7.8 K

For Research Use Only. Not for use in diagnostic procedures

The Twist Alliance CNTG Rare Disease Panel includes more than 2,500 relevant rare disease-associated genes and covers ≥99.5% of targeted regions, offering researchers a more lightweight tool for capturing the crucial rare disease coverage in the CNTG Exome without the full footprint. This panel can be used to detect genes associated with but not limited to rare treatable diseases, early onset childhood disorders, cardiac disorders, neurodegenerative diseases, skeletal abnormalities and metabolic disorders.  

• Twist Alliance Centogene Rare Disease Panel 78.8 K probes

Note: The Twist Alliance CNTG Rare Disease Panel-7.6MB  is not ISO-13485 certified.

For Research Use Only. Not for use in diagnostic procedures

The Twist Alliance CNTG Hereditary Oncology Panel includes 72 selected cancer-associated genes and covers ≥99.5% of targeted regions. The panel can be used to identify genetic predisposition to hereditary tumors including breast cancer, gastrointestinal tumors, Li-Fraumeni syndrome, MEN1, MEN2, paragangliomas and others.

Note: The Twist Alliance CNTG Hereditary Oncology Panel- 0.2MB is not ISO-13485 certified.